AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26
Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice
Authors: Xiang, R Silletti, S Lode, HN Dolman, CS Ruehlmann, JM Niethammer, AG Pertl, U Gillies, SD Primus, FJ Reisfeld, RA
Citation: R. Xiang et al., Protective immunity against human carcinoembryonic antigen (CEA) induced by an oral DNA vaccine in CEA-transgenic mice, CLIN CANC R, 7(3), 2001, pp. 856S-864S
Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue
Authors: Schrama, D Straten, PT Fischer, WH McLellan, AD Brocker, EB Reisfeld, RA Becker, JC
Citation: D. Schrama et al., Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue, IMMUNITY, 14(2), 2001, pp. 111-121
An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice
Authors: Niethammer, AG Primus, FJ Xiang, R Dolman, CS Ruehlmann, JM Ba, Y Gillies, SD Reisfeld, RA
Citation: Ag. Niethammer et al., An oral DNA vaccine against human carcinoembryonic antigen (CEA) prevents growth and dissemination of Lewis lung carcinoma in CEA transgenic mice, VACCINE, 20(3-4), 2001, pp. 421-429
In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy
Authors: Shabat, D Lode, HN Pertl, U Reisfeld, RA Rader, C Lerner, RA Barbas, CF
Citation: D. Shabat et al., In vivo activity in a catalytic antibody-prodrug system: Antibody catalyzed etoposide prodrug activation for selective chemotherapy, P NAS US, 98(13), 2001, pp. 7528-7533
A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancerin carcinoembryonic antigen-transgenic mice
Authors: Xiang, R Primus, FJ Ruehlmann, JM Niethammer, AG Silletti, S Lode, HN Dolman, CS Gillies, SD Reisfeld, RA
Citation: R. Xiang et al., A dual-function DNA vaccine encoding carcinoembryonic antigen and CD40 ligand trimer induces T cell-mediated protective immunity against colon cancerin carcinoembryonic antigen-transgenic mice, J IMMUNOL, 167(8), 2001, pp. 4560-4565
IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy
Authors: Pertl, U Luster, AD Varki, NM Homann, D Gaedicke, G Reisfeld, RA Lode, HN
Citation: U. Pertl et al., IFN-gamma-inducible protein-10 is essential for the generation of a protective tumor-specific CD8 T cell response induced by single-chain IL-12 gene therapy, J IMMUNOL, 166(11), 2001, pp. 6944-6951
In situ cytokine therapy: redistribution of clonally expanded T cells
Authors: Straten, PT Guldberg, P Schrama, D Andersen, MH Moerch, U Seremet, T Siedel, C Reisfeld, RA Becker, JC
Citation: Pt. Straten et al., In situ cytokine therapy: redistribution of clonally expanded T cells, EUR J IMMUN, 31(1), 2001, pp. 250-258
The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy
Authors: Imboden, M Murphy, KR Rakhmilevich, AL Neal, ZC Xiang, R Reisfeld, RA Gillies, SD Sondel, PM
Citation: M. Imboden et al., The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy, CANCER RES, 61(4), 2001, pp. 1500-1507
MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma
Authors: Ruehlmann, JM Xiang, R Niethammer, AG Ba, Y Perti, U Dolman, CS Gillies, SD Reisfeld, RA
Citation: Jm. Ruehlmann et al., MIG (CXCL9) chemokine gene therapy combines with antibody-cytokine fusion protein to suppress growth and dissemination of murine colon carcinoma, CANCER RES, 61(23), 2001, pp. 8498-8503
Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma
Authors: Niethammer, AG Xiang, R Ruehlmann, JM Lode, HN Dolman, CS Gillies, SD Reisfeld, RA
Citation: Ag. Niethammer et al., Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma, CANCER RES, 61(16), 2001, pp. 6178-6184
Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors
Authors: Yun, CO Nolan, KF Beecham, EJ Reisfeld, RA Junghans, RP
Citation: Co. Yun et al., Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors, NEOPLASIA, 2(5), 2000, pp. 449-459
Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: A Children's Cancer Group Study
Authors: Ozkaynak, MF Sondel, PM Krailo, MD Gan, J Javorsky, B Reisfeld, RA Matthay, KK Reaman, GH Seeger, RC
Citation: Mf. Ozkaynak et al., Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: A Children's Cancer Group Study, J CL ONCOL, 18(24), 2000, pp. 4077-4085
Clinical and immune responses in advanced melanoma patients immunized withan anti-idiotype antibody mimicking disialoganglioside GD2
Authors: Foon, KA Lutzky, J Baral, RN Yannelli, JR Hutchins, L Teitelbaum, A Kashala, OL Das, R Garrison, J Reisfeld, RA Bhattacharya-Chatterjee, M
Citation: Ka. Foon et al., Clinical and immune responses in advanced melanoma patients immunized withan anti-idiotype antibody mimicking disialoganglioside GD2, J CL ONCOL, 18(2), 2000, pp. 376-384
Targeted cytokines for cancer immunotherapy
Authors: Lode, HN Reisfeld, RA
Citation: Hn. Lode et Ra. Reisfeld, Targeted cytokines for cancer immunotherapy, IMMUNOL RES, 21(2-3), 2000, pp. 279-288
Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma
Authors: Lode, HN Pertl, U Xiang, R Gaedicke, G Reisfeld, RA
Citation: Hn. Lode et al., Tyrosine hydroxylase-based DNA-vaccination is effective against murine neuroblastoma, MED PED ONC, 35(6), 2000, pp. 641-646
Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma (vol 95, pg 2475, 1998)
Authors: Lode, HN Dreier, T Xiang, R Varki, NM Kang, AS Reisfeld, RA
Citation: Hn. Lode et al., Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma (vol 95, pg 2475, 1998), P NAS US, 97(7), 2000, pp. 3782-3782
An autologous oral DNA vaccine protects against murine melanoma (vol. 97, pg. 5492, 2000)
Authors: Xiang, R Lode, HN Chao, TH Ruehlmann, JM Dolman, CS Rodriguez, F Whitton, JL Overwijk, WW Restifo, NP Reisfeld, RA
Citation: R. Xiang et al., An autologous oral DNA vaccine protects against murine melanoma (vol. 97, pg. 5492, 2000), P NAS US, 97(23), 2000, pp. 12932-12932
Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma
Authors: Balicki, D Reisfeld, RA Pertl, U Beutler, E Lode, HN
Citation: D. Balicki et al., Histone H2A-mediated transient cytokine gene delivery induces efficient antitumor responses in murine neuroblastoma, P NAS US, 97(21), 2000, pp. 11500-11504
An autologous oral DNA vaccine protects against murine melanoma
Authors: Xiang, R Lode, HN Chao, TH Ruehlmann, JM Dolman, CS Rodriguez, F Whitton, JL Overwijk, WW Restifo, NP Reisfeld, RA
Citation: R. Xiang et al., An autologous oral DNA vaccine protects against murine melanoma, P NAS US, 97(10), 2000, pp. 5492-5497
What to do with targeted IL-2
Authors: Lode, HN Xiang, R Perri, P Pertl, U Lode, A Gillies, SD Reisfeld, RA
Citation: Hn. Lode et al., What to do with targeted IL-2, DRUGS TODAY, 36(5), 2000, pp. 321-336
Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction
Authors: Lode, HN Xiang, R Pertl, U Forster, E Schoenberger, SP Gillies, SD Reisfeld, RA
Citation: Hn. Lode et al., Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction, J CLIN INV, 105(11), 2000, pp. 1623-1630
The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro
Authors: Batova, A Kamps, A Gillies, SD Reisfeld, RA Yu, AL
Citation: A. Batova et al., The Ch14.18-GM-CSF fusion protein is effective at mediating antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity in vitro, CLIN CANC R, 5(12), 1999, pp. 4259-4263
Synergy between an antiangiogenic integrin alpha(v) antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases
Authors: Lode, HN Moehler, T Xiang, R Jonczyk, A Gillies, SD Cheresh, DA Reisfeld, RA
Citation: Hn. Lode et al., Synergy between an antiangiogenic integrin alpha(v) antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases, P NAS US, 96(4), 1999, pp. 1591-1596
Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12
Authors: Lode, HN Xiang, R Duncan, SR Theofilopoulos, AN Gillies, SD Reisfeld, RA
Citation: Hn. Lode et al., Tumor-targeted IL-2 amplifies T cell-mediated immune response induced by gene therapy with single-chain IL-12, P NAS US, 96(15), 1999, pp. 8591-8596
T cell memory against colon carcinoma is long-lived absence of antigen
Authors: Xiang, R Lode, HN Gillies, SD Reisfeld, RA
Citation: R. Xiang et al., T cell memory against colon carcinoma is long-lived absence of antigen, J IMMUNOL, 163(7), 1999, pp. 3676-3683
Risultati: 1-25 | 26-26